cbdMD, Inc. (NYSEAMERICAN:YCBD – Get Free Report) saw a large drop in short interest in December. As of December 31st, there was short interest totaling 1,234,477 shares, a drop of 68.9% from the December 15th total of 3,970,725 shares. Currently, 12.5% of the shares of the company are sold short. Based on an average daily volume of 24,116,987 shares, the short-interest ratio is currently 0.1 days. Based on an average daily volume of 24,116,987 shares, the short-interest ratio is currently 0.1 days. Currently, 12.5% of the shares of the company are sold short.
Insider Transactions at cbdMD
In other cbdMD news, major shareholder Clark R. Crosnoe sold 550,701 shares of the company’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $2.32, for a total value of $1,277,626.32. Following the completion of the transaction, the insider owned 17,875 shares in the company, valued at approximately $41,470. This represents a 96.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 2.10% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On cbdMD
An institutional investor recently raised its position in cbdMD stock. Chapin Davis Inc. lifted its stake in cbdMD, Inc. (NYSEAMERICAN:YCBD – Free Report) by 62.5% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 118,626 shares of the company’s stock after purchasing an additional 45,626 shares during the quarter. Chapin Davis Inc. owned 1.33% of cbdMD worth $106,000 as of its most recent filing with the Securities & Exchange Commission. 7.18% of the stock is currently owned by institutional investors and hedge funds.
cbdMD Price Performance
cbdMD Company Profile
cbdMD, Inc (NYSEAMERICAN: YCBD) is a Charlotte, North Carolina–based producer and distributor of hemp-derived cannabidiol (CBD) products. Since its founding in 2018, the company has focused on developing a diverse portfolio of wellness offerings designed for human and pet use. Its product range includes tinctures, capsules, gummies, topicals, and pet-specific formulations, each developed to comply with U.S. Food and Drug Administration (FDA) guidelines for hemp-derived substances.
The company operates a vertically integrated business model, sourcing U.S.-grown hemp and overseeing manufacturing processes in cGMP-certified facilities.
Featured Articles
- Five stocks we like better than cbdMD
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
- This stock gets a 94 out of 100
Receive News & Ratings for cbdMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for cbdMD and related companies with MarketBeat.com's FREE daily email newsletter.
